Literature DB >> 26141049

Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma.

Tasmin Reuter1, Rolf Warta2,3, Dirk Theile1, Andreas D Meid1, Juan Pablo Rigalli1, Carolin Mogler4,5, Esther Herpel4,5, Niels Grabe6,7, Bernd Lahrmann5,7, Peter K Plinkert8, Christel Herold-Mende2,3, Gerhard Dyckhoff3, Walter Emil Haefeli1, Johanna Weiss9.   

Abstract

The pregnane X receptor (PXR) is a transcription factor regulating genes involved not only in pharmacokinetics but also in chemotherapy resistance and cancer progression. The significance of PXR for survival of head and neck squamous cell carcinoma (HNSCC) patients is unknown so far. Single nucleotide polymorphisms (SNPs) in the PXR-encoding NR1I2 gene influence receptor functionality and inducibility by ligands and thus modulate expression and activity of its target genes. In this study, seven SNPs in the NR1I2 gene were investigated for an association with PXR protein expression and survival of HNSCC patients. Genotyping was conducted using hybridisation probe format methodology. PXR protein expression was quantified by immunohistochemistry of tissue microarray samples of HNSCC biopsies. Genotypes were correlated to PXR protein expression by a linear model regressing on the continuous gene expression value and a Cox model regressing on overall survival times. Haplotype analysis was performed by reconstruction of haplotypes from genotype information according to the expectation-maximisation algorithm. Of all tested SNPs, rs1054190 and rs1054191 allele variants tended to correlate with a reduced protein expression score of PXR (p = 0.088). Four haplotypes, each consisting of two SNPs, rs3814055/rs1054190 and rs3814055/rs1054191 as well as rs1523127/rs1054190 and rs1523127/rs1054191, showed a significant reduction of the PXR expression score (p = 0.049 and p = 0.032). However, neither allele variants nor haplotypes influenced overall survival of the respective patients. Certain NR1I2 SNPs showed an impact on PXR protein expression in HNSCC but did not influence overall survival times, questioning their value as prognostic biomarkers.

Entities:  

Keywords:  Genotype/phenotype correlation; Head and neck squamous cell carcinoma; NR1I2 polymorphism; Pregnane X receptor

Mesh:

Substances:

Year:  2015        PMID: 26141049     DOI: 10.1007/s00210-015-1150-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  43 in total

Review 1.  Genetic alterations in head and neck cancer: interactions among environmental carcinogens, cell cycle control, and host DNA repair.

Authors:  C Y Fan
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

2.  Tumor evolution and intratumor heterogeneity of an oropharyngeal squamous cell carcinoma revealed by whole-genome sequencing.

Authors:  Xinyi Cindy Zhang; Chang Xu; Ryan M Mitchell; Bo Zhang; Derek Zhao; Yao Li; Xin Huang; Wenhong Fan; Hongwei Wang; Luisa Angelica Lerma; Melissa P Upton; Ashley Hay; Eduardo Méndez; Lue Ping Zhao
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Impact of drug transporters on cellular resistance towards saquinavir and darunavir.

Authors:  Sonja Katharina König; Melanie Herzog; Dirk Theile; Nadine Zembruski; Walter Emil Haefeli; Johanna Weiss
Journal:  J Antimicrob Chemother       Date:  2010-09-03       Impact factor: 5.790

4.  Steroid and Xenobiotic Receptor (SXR) as a possible prognostic marker in epithelial ovarian cancer.

Authors:  Xiaoni Yue; Jun-ichi Akahira; Hiroki Utsunomiya; Yasuhiro Miki; Naomi Takahashi; Hitoshi Niikura; Kiyoshi Ito; Hironobu Sasano; Kunihiro Okamura; Nobuo Yaegashi
Journal:  Pathol Int       Date:  2010-05       Impact factor: 2.534

5.  Polymorphisms in NF-κB, PXR, LXR, PPARγ and risk of inflammatory bowel disease.

Authors:  Vibeke Andersen; Jane Christensen; Anja Ernst; Bent A Jacobsen; Anne Tjønneland; Henrik B Krarup; Ulla Vogel
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

6.  The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Gustavo O Castaño; Adriana L Burgueño; Tomas Fernández Gianotti; María Soledad Rosselli; Carlos Jose Pirola
Journal:  Pharmacogenet Genomics       Date:  2010-01       Impact factor: 2.089

7.  Serum biomarkers in head and neck squamous cell cancer.

Authors:  Nadine M Kaskas; Tara Moore-Medlin; Gloria B McClure; Oleksandr Ekshyyan; John A Vanchiere; Cherie-Ann O Nathan
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-01       Impact factor: 6.223

8.  Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.

Authors: 
Journal:  Int J Cancer       Date:  2010-06-15       Impact factor: 7.396

9.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

10.  Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha.

Authors:  Isabel Conde; María V T Lobo; Javier Zamora; Julio Pérez; Francisco J González; Emilio Alba; Benito Fraile; Ricardo Paniagua; María I Arenas
Journal:  BMC Cancer       Date:  2008-06-19       Impact factor: 4.430

View more
  3 in total

1.  Easy-to-use strategy for reference gene selection in quantitative real-time PCR experiments.

Authors:  Stefanie Klenke; Kristina Renckhoff; Andrea Engler; Jürgen Peters; Ulrich H Frey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-20       Impact factor: 3.000

2.  Pregnane X Receptor and Cancer: Context-Specificity is Key.

Authors:  Satyanarayana R Pondugula; Petr Pavek; Sridhar Mani
Journal:  Nucl Receptor Res       Date:  2016-06-12

3.  Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI.

Authors:  Elena De Mattia; Jerry Polesel; Rossana Roncato; Adrien Labriet; Alessia Bignucolo; Eva Dreussi; Loredana Romanato; Michela Guardascione; Angela Buonadonna; Mario D'Andrea; Eric Lévesque; Derek Jonker; Félix Couture; Chantal Guillemette; Erika Cecchin; Giuseppe Toffoli
Journal:  Front Oncol       Date:  2019-11-26       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.